%0 Conference Paper
%A Palleis, Carla
%A Franzmeier, Nicolai
%A Gnoerich, Johannes
%A Jäck, Alexander
%A Bernhardt, Alexander M
%A Katzdobler, Sabrina
%A Fietzek, Urban
%A Weidinger, Endy
%A Frontzkowski, Lukas
%A Roemer-Cassiano, Sebastian
%A Zwergal, Andreas
%A Barthel, Henryk
%A Sabri, Osama
%A Levin, Johannes
%A Höglinger, Günter U
%A Brendel, Matthias
%T Clinical value of 18 F‐PI2620‐PET in the diagnostic workup of patients with suspected Progressive Supranuclear Palsy
%J Alzheimer's and dementia
%V 21
%N S2
%@ 1552-5260
%M DZNE-2025-01449
%P e102121
%D 2025
%X Background:Progressive Supranuclear Palsy (PSP) is a rapidly progressing 4-repeat tauopathy, presenting with clinically heterogeneous phenotypes. Currently, diagnoses are based solely on clinical criteria but reliable diagnostic classification remains particularly challenging at early stages. 18F-PI-2620 tau-PET is an evolving neuroimaging biomarker to capture 4-repeat tau (4RT) deposits in vivo with clear diagnostic potential in research settings. To determine the added clinical value of 18F-PI-2620 tau-PET in the diagnostic workup of PSP, we evaluated whether 18F-PI-2620-assessed 4RT positivity (i.e. using the basal ganglia as a target readout) predicts subsequent increases of diagnostic certainty for PSP, indicative of 4RT pathology driving clinical progression.Method:We collected monocentric longitudinal data at the LMU Hospital in Munich, from a non-randomized prospective cohort study between October 2018 and December 2024. Data collection included pre-PET visits with routine clinical classification following the MDS criteria. In addition, we performed 18F-PI-2620 tau-PET with dichotomous visual read assessments of 4RT pathology by an expert reader and collected clinical follow-up data or autopsy information.Results:342 patients with a pre-PET differential diagnosis of PSP were referred to 18F-PI-2620 tau-PET in clinical routine. Of those, 200 patients (61.5
%B Alzheimer’s Association International Conference
%C 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2 27 Jul 2025 - 31 Jul 2025
M2 Toronto, Canada
%K Humans
%K Supranuclear Palsy, Progressive: diagnostic imaging
%K Supranuclear Palsy, Progressive: diagnosis
%K Supranuclear Palsy, Progressive: metabolism
%K Male
%K Female
%K tau Proteins: metabolism
%K Biomarkers: metabolism
%K Positron-Emission Tomography
%K Aged
%K Longitudinal Studies
%K Prospective Studies
%K Middle Aged
%K Disease Progression
%K tau Proteins (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
%9 AbstractJournal Article
%R 10.1002/alz70856_102121
%U https://pub.dzne.de/record/283042